1	
2	
3	
4	High prevalence of long-term olfactory disorders in healthcare workers after
5	COVID-19: a case-control study
6	
7	Johannes Frasnelli <sup>1, 2¶</sup> , Arnaud Tognetti <sup>1,3¶</sup> , Anja L. Winter <sup>1</sup> , Evelina Thunell <sup>1</sup> , Mats J. Olsson <sup>1</sup> , Nina
8	Greilert <sup>4</sup> , Jonas K. Olofsson <sup>5</sup> , Sebastian Havervall <sup>4</sup> , Charlotte Thålin <sup>4&amp;</sup> , and Johan N. Lundström <sup>1, 6&amp;</sup>
9	
10	<sup>1</sup> Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
11	<sup>2</sup> Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivieres, QC, Canada
12	<sup>3</sup> CEE-M, CNRS, INRAE, Institut Agro, University of Montpellier, Montpellier, France
13	<sup>4</sup> Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden
14	<sup>5</sup> Department of Psychology, Stockholm University, Stockholm, Sweden
15	<sup>6</sup> Monell Chemical Senses Center, Philadelphia, PA, USA
16	
17	* Corresponding Author:
18	E-mail: Johan.Lundstrom@ki.se (JL)
19	<sup>¶</sup> JF and AT share first authorship.
20	<sup>&amp;</sup> CT and JNL are Joint Senior Authors.
21	
22	

# 23 Abstract

Background More than a year after recovering from COVID-19, a large proportion of individuals, many of whom work in the healthcare sector, still report olfactory dysfunctions. However, olfactory dysfunction was common already before the COVID-19 pandemic, making it necessary to also consider the existing baseline prevalence of olfactory dysfunction. To establish the adjusted prevalence of COVID-19 related olfactory dysfunction, we assessed smell function in healthcare workers who had contracted COVID-19 during the first wave of the pandemic using psychophysical testing.

Methods: Participants were continuously tested for SARS-CoV-2 IgG antibodies since the beginning of the
 pandemic. To assess the baseline rate of olfactory dysfunction in the population and to control for the
 possibility of skewed recruitment of individuals with prior olfactory dysfunction, consistent SARS-CoV-2
 IgG naïve individuals were tested as a control group.

Results: Fifteen months after contracting COVID-19, 37% of healthcare workers demonstrated a
quantitative reduction in their sense of smell, compared to only 20% of the individuals in the control group.
Fifty-one percent of COVID-19-recovered individuals reported qualitative symptoms, compared to only 5%
in the control group. In a follow-up study 2.6 years after COVID-19 diagnosis, 24% of all tested recovered
individuals still experienced parosmia.

Conclusions: In summary, 65% of healthcare workers experienced parosmia/hyposmia 15 months after contracting COVID-19. When compared to a control group, the prevalence of olfactory dysfunction in the population increased by 41 percentage points. Parosmia symptoms were still lingering two-and-a half years later in 24% of SARS-CoV-2 infected individuals. Given the amount of time between infection and testing, it is possible that the olfactory problems may not be fully reversible in a plurality of individuals.

44

45 Keywords: COVID-19; Long COVID; Olfactory dysfunction; Parosmia;

# 46 Introduction

Olfactory dysfunction is the most specific symptom of acute COVID-19 [1–3] and our ability to smell can be heavily impacted by the disease [4]. In many patients, olfactory function is regained after the acute phase [5], yet a non-negligeable proportion of patients exhibits chronic dysfunction [6]. Estimations of the prevalence of olfactory dysfunction 6 months after COVID-19, the threshold for chronicity of olfactory dysfunction, vary widely [5,7–13]. A recent assessment of olfactory dysfunction based on subjective reports suggests that a staggering 61% still experience olfactory dysfunction two years after infection [6].

53 Despite the clear evidence that COVID-19 can result in long-term olfactory dysfunction, there are 54 several caveats in current prevalence estimates that may account for the large differences in reported 55 estimates. First, most of the estimations are based on self-reported olfactory dysfunction which is 56 notoriously unreliable [14,15]. Second, COVID-19 status is seldom determined by biological assays but 57 rather by self-reported status, which can bias the estimations. Third, the prevalence of olfactory dysfunction 58 unrelated to COVID-19 is usually not considered. In fact, olfactory dysfunction in the general population 59 was estimated to be around 20% before the pandemic [16–19], with leading causes being sinonasal diseases, 60 traumatic brain injuries, and viral infections of the upper respiratory tract [20]. Thus, an accurate estimate 61 of the prevalence of olfactory dysfunction after COVID-19 infection requires consideration of the 62 prevalence of olfactory dysfunction in a sample where COVID-19 infection can be ruled out.

Olfactory dysfunction encompasses various impairments to the sense of smell, categorized into quantitative dysfunction, involving a reduction or loss of olfactory function (hyposmia or anosmia) [19], and qualitative dysfunction, which involves altered odor perception such as parosmia or phantosmia. Standardized assessments of parosmia and phantosmia can currently only be carried out using questionnaires [21] due to their subjective nature. While self-evaluation questionnaires are commonly used to assess quantitative dysfunction, their precision warrants caution in interpretation[14,15]. Therefore, when estimating the prevalence of olfactory dysfunction after COVID-19, a comprehensive approach should

incorporate both questionnaires and well-validated gold standard psychophysical tests [22,23] for a more
accurate assessment of objective and subjective aspects.

72 Healthcare workers may be particularly affected by long-term consequences of COVID-19. For 73 example, mental health disorders were particularly high in this population both during and following 74 COVID-19 [24,25]. In line with this, nearly half of infected healthcare workers reported reduced 75 chemosensory abilities one year after COVID-19 [5], which is considerably higher than in the general 76 population [26]. It is therefore particularly valuable to study the long-term effects of COVID-19 on olfactory 77 function in this group. We designed this study to assess olfactory dysfunction in a sample of healthcare 78 workers where continuous serum assessments of SARS-CoV-2 infection were available. Specifically, we 79 included two groups of participants; one group that had undergone SARS-CoV-2 infection and a control 80 group that had not, as confirmed by the continuous serum testing. Our objective was to establish the 81 prevalence of olfactory dysfunction due to COVID-19 up to 15 months after infection by evaluating 82 olfactory dysfunction with validated olfactory tests in both groups. We hypothesized that the group who had 83 undergone SARS-CoV-2 infection would be afflicted by a significantly higher prevalence of olfactory 84 dysfunction compared to the control group.

85

## 86 Materials and method

### 87 **Participants**

All participants were recruited from the ongoing COMMUNITY (COVID-19 Immunity) study that enrolled 2149 healthcare workers employed at Danderyd Hospital, Stockholm in April 2020. All participants were tested for SARS-CoV-2 IgG antibodies every four months since the beginning of the pandemic [2], see <u>https://ki.se/en/kids/community</u> for more information. We screened out individuals with acute nasal congestion/rhinorrhea, neurodegenerative diseases, and other conditions associated with reduced olfactory

93 function. All participants gave written informed consent, and the study was approved by the Swedish Ethical
94 Review Authority (dnr 2021-02052).

95 We recruited healthcare workers that had contracted COVID-19 during the first wave in Stockholm 96 between January and May 2020. Of a total of 320 SARS-CoV-2 IgG positive individuals, 100 participated 97 in the current study. Two were excluded due to an inability to perform the tests, leaving a final sample of 98 98 COVID+ participants (average age: 48 years; SD  $\pm 12$ ; 84 women; average time since infection 447, SD 99  $\pm$ 73, days). All participants had experienced mild COVID-19 and had not required hospitalization. We 100 further invited an equal number of SARS-CoV-2 naïve, meaning SARS-CoV-2 IgG negative during all 101 sampling timepoints since enrollment, healthcare workers from the same cohort with a similar age profile. 102 A total of 44 individuals were included, with 3 individuals subsequently excluded due to olfactory-related 103 sickness, excessive construction noise during testing precluding concentration, and refusal to perform some 104 tests. This resulted in a final control sample of 41 COVID- participants (average age: 51 years; SD  $\pm 11$ ; 38 105 women).

#### 106 Chemosensory assessments

#### 107 Quantitative olfactory dysfunction

108 Quantitative olfactory dysfunction was assessed using two different approaches. First, we assessed 109 subjective quantitative olfactory function using a 10-point visual analog scale. Participants responded to the 110 question "How has your sense of smell been during the last three days?"; the scale ranged from 0 (no smell) 111 to 10 (very good sense of smell). Second, we assessed objective quantitative olfactory function 112 psychophysically, using the Sniffin' Sticks test battery [23]. This test is based on felt-tip pen-like odor 113 dispensing devices and allows for separate assessments of the ability to discriminate (D) and identify (I) 114 odors as well as an olfactory detection threshold (T). To assess odor quality discrimination, 16 triplets of 115 pens were presented to the participant. Each triplet consisted of two pens with identical odorants and one 116 with an odorant of different quality. To evaluate odor identification abilities, we used a forced-choice cued 117 identification task using 16 different odorants. Each odor was presented together with a cue card listing four

alternative odor labels, and the participant picked the label that best described the quality of the perceived odor. To estimate odor detection thresholds, we used the odor n-Butanol in a three-alternative forced-choice staircase procedure with seven reversals in a 16-step binary dilution series. The individual sub-scores were then combined to a global TDI score, for which normative data are available and allows for the diagnosis of normosmia, hyposmia, and functional anosmia [27].

#### 123 **Qualitative olfactory dysfunction**

124 Qualitative olfactory dysfunction was assessed using a questionnaire containing four items [21]. The 125 questionnaire addressed aspects of qualitative olfactory dysfunction with regards to alterations in food 126 perception, the presence of odors in absence of an odor source, pleasantness of perceived odors, and the 127 impact of the perception of altered odors; participants could respond using a 4-point scale ranging from 1 128 (never) to 4 (always). We analyzed the questionnaire in two ways: first, we calculated the sum score of all 129 four items (Parosmia score). Then, we counted the number of participants who responded *always*, often, or 130 rarely to the question "the biggest problem is not that I do not or weakly perceive odors, but that they smell 131 *different than they should* vs those who responded *never* (Parosmia presence).

#### 132 Serological analyses of antibodies

133 A detailed description of serological analyses has been presented elsewhere [2]. Briefly, IgG reactivity was 134 measured towards three different SARS-CoV-2 virus protein variants, Spike trimers, Spike S1 domain, and 135 Nucleocapsid protein, and analyzed using a multiplex antigen bead array in high throughput 384-plates form 136 at using a FlexMap3D (Luminex Corp)[28]. To be assigned to the SARS-CoV-2 IgG positive group, 137 reactivity against at least two of the three different variants of the viral antigens was required, calculated to 138 have 99.2% sensitivity and 99.8% specificity [2]. We did not determine individual virus variants but random 139 sampling of the Stockholm population during the time participants in this study were infected showed that 140 three main strains of Variants Being Monitored (VBM) of the SARS-CoV-2 dominated, namely the 141 Wildtype, and to a lesser extent, the B.1.1/B.1.1.29 and B.1.1.1/C.14 [29].

## 142 **Procedure**

Olfactory dysfunction data were collected between June and November 2021. Upon inclusion, participants responded to a questionnaire containing the VAS and the parosmia questions before the Sniffin' Sticks test battery was administered. The total testing time was 1.5 h and participants received monetary compensation for their participation.

#### 147 Follow-up

To further estimate the persistence of qualitative olfactory dysfunction, participants diagnosed with established parosmia were contacted approximately one year after their initial participation for a follow-up conducted via phone. Out of the 48 participants contacted, 41 individuals responded to the follow-up assessment (with an average time since infection of 963 days, i.e., over 2.6 years since onset; SD  $\pm$ 64 days), which featured identical questions and response options as those used during the initial assessment.

#### 153 Statistics

To assess whether an infection with SARS-CoV-2 correlated with long-term quantitative and/or qualitative olfactory dysfunction we compared scores on the (a) parosmia questionnaire (4 COVID+ and 3 COVIDindividuals refrained from answering this questionnaire), (b) quantitative subjective olfactory dysfunction scale, and (c) Sniffin' Sticks test between COVID+ and COVID- groups. To correct for the uneven sample size between the two groups as well as the non-normal distribution of the variables, we performed nonparametric statistical group comparisons using a two-sided Wilcoxon rank sum test with continuity correction. We also compared frequencies between groups using chi-square tests.

#### 161 Availability of data materials


162 The datasets generated along with associated scripts and figures are available on the Open Science

163 Framework data depository <u>https://osf.io/hja2p/?view\_only=53d8bb21c06c48d2bee231f75797789c</u>

## 165 **Results**

166 First, we assessed quantitative olfactory dysfunction. To do so, we explored potential differences in 167 subjective performance: here, participants from the COVID+ group (N = 98) evaluated their olfactory 168 function as significantly worse, 6.9 (SD  $\pm 2.5$ ) out of a total of 10 points compared to the COVID- group (N 169 = 41), 8.9 points ( $SD \pm 1.2$ ; W = 955; N = 139, p < .0001). In line with the subjective experience, the average 170 Sniffin' Sticks TDI score was also significantly lower in the COVID+ group according to a Wilcoxon rank 171 sum test, 30.9 points (SD  $\pm$ 5.9), compared to the COVID- group, 34.0 points (SD  $\pm$ 3.4; W =1416.5; N = 172 139, p = .006; Figure 1A). Interestingly, upon separate analysis of the TDI subscales, only discrimination 173 (W = 1293; N = 139, p = .0008; Figure 1C) and identification (W = 1213.5; N = 139, p = .0002; Figure 1D)174 subscores were significantly lower in the COVID+ group (D =  $11.66 \pm 2.5$ , I =  $12.11 \pm 2.5$ ) compared to 175 the COVID- group (D =  $13.19 \pm 1.9$ , I =  $13.68 \pm 1.3$ ). However, no statistically significant difference (W = 176 2107; N = 139, p = .65; Figure 1B) was observed for the threshold subscore between the two groups 177  $(COVID + = 7.10 \pm 2.4, COVID = 7.11 \pm 2.0)$ . We then assessed the proportion of individuals with a 178 clinically relevant quantitative olfactory dysfunction. Based on the TDI score, the frequency of quantitative olfactory dysfunction was significantly higher ( $X^2$  (1, N = 139) = 6.28, p = .01) in the COVID+ group 179 180 compared to the COVID- group. A total of 37% of the COVID+ group suffered quantitative olfactory 181 dysfunction, with 4 individuals exhibiting anosmia (TDI score =  $14.88 \pm 2.0$ ) and 32 individuals exhibiting 182 hyposmia (TDI score =  $26.11 \pm 3.9$ ). In the COVID- group, 20% (N = 8) showed quantitative olfactory 183 dysfunction, all of whom had hyposmia (TDI score =  $29.56 \pm 0.8$ ). The average TDI scores for individuals 184 with normosmia were 34.38 (SD = 2.6) and 35.06 (SD = 2.8) for the COVID+ and the COVID- groups, 185 respectively. Last, we investigated whether the degree of quantitative olfactory dysfunction was influenced 186 by the time since COVID-19 infection and individuals' age. A Spearman correlation test indicated that the 187 TDI score of individuals from the COVID+ group was not significantly affected by the number of days 188 since infection (N = 71, r = -1, p = .43; see Supplementary Figure S1A). However, TDI significantly 189 declined with age in the COVID+ group (Spearman correlation test, r = -.28, p = .005, Supplementary Figure

#### 190 S1B). It's worth noting that in the COVID- group, a similar negative relationship between TDI and age was








Figure 1. Quantitative olfactory dysfunctions for COVID-19 positive (COVID+, N = 98) and COVID-19 naïve (COVID-, N = 41) groups. (A) Mean TDI scores for COVID+ and COVID- groups with error bars denoting standard deviation (SD) as well as values for each participant indicated by circles. Dashed lines indicate cut-off scores for the clinical diagnoses Hyposmia (threshold score: 30.75) and Anosmia (threshold score: 16.25). Higher TDI scores (possible range 1-48) indicate better olfactory performance. TDI subscale scores for the COVID+ and COVID- groups are presented with error bars denoting standard deviation (SD) for (B) Threshold, (C) Discrimination, and (D) Identification scores separately.

Next, we assessed to what level individuals in the respective groups experienced qualitative olfactory dysfunction using the 4-item parosmia scale. The average score was significantly higher in the COVID+ group, 2.8 points ( $SD \pm 2.8$ ), compared to the COVID- group, 0.7 points ( $SD \pm 1.2$ ; Wilcoxon rank sum, W = 2595; N = 132, p < .0001; Figure 2A). Correspondingly, we found that significantly more individuals from the COVID+ group reported parosmia (48 of 94 participants, 51%) relative to individuals from the COVID- group (2 of 38 participants, 5%;  $X^2$  (1, N = 132) = 22.2, p < .0001). To understand the

degree of symptom severity, we also assessed the answers to the parosmia severity question in each group.
As can be seen in Figure 2B, slightly more than half of the individuals in the COVID+ group who reported
parosmia symptoms experienced only minor symptoms (None 49%, Mild, 28%, Medium 16%, Severe 7%).
This means that about a quarter of all individuals in the COVID+ group experienced medium to severe
parosmia symptoms 15 months after COVID-19.




Figure 2. Distribution of parosmia score. A) Distribution of scores per patient group (N = 94), COVID-19 positive (COVID+) and COVID-19 naïve (COVID-, N = 38), on the Landis parosmia questionnaire. B) Percentage of individuals in each patient group, grouped by reported parosmia severity score. C) Proportion of COVID+ participants (N = 94) in each olfactory dysfunction classification group.

217

Further, we followed up with 48 individuals from the COVID+ group with established parosmia 2.6 years after COVID-19 infection. Of the 41 individuals who responded, 23 (56% of sub-sample, 24% of total initial COVID+ sample) still experienced parosmia. In fact, 41% indicated that they experienced medium to severe parosmia symptoms (None 43.9%, Mild, 14.6%, Medium 31.7%, Severe 9.8%). This long-lasting qualitative olfactory dysfunction was also reflected by a high parosmia score  $(3.1 \pm 2.3 \text{ points})$ .

As to be expected, there was a considerable comorbidity between diagnoses. While 35% of the COVID+ group (total N = 94) experienced no olfactory dysfunction at all, 14% experienced anosmia/hyposmia but no parosmia, 29% experienced parosmia but no anosmia/hyposmia, and 22%

226 experienced both anosmia/hyposmia and parosmia. In other words, a total of 65% of COVID+ participants 227 experienced some form of olfactory dysfunction on average 15 months after COVID-19 (Figure 2C). This 228 frequency was lower in the COVID- group (N = 38) where only 24% experienced some form of olfactory 229 dysfunction, 76% experienced no olfactory dysfunction, none had anosmia, 18% experienced hyposmia but 230 no parosmia, 3% experienced parosmia but no hyposmia, and 3% experienced both hyposmia and 231 parosmia). As expected, the frequency of combined quantitative and qualitative olfactory dysfunction was 232 significantly lower in the COVID- group compared to the COVID+ group  $(X^2(1, N = 132) = 32.4, p < 10^{-1})$ 233 .0001). This means that COVID-19 increased olfactory dysfunction (parosmia, hyposmia, or parosmia and 234 hyposmia) with 41 percentage points (COVID+: 65%; COVID-: 24%) 15 months after COVID-19 onset.

235

## 236 **Discussion**

237 More than a year after recovering from COVID-19, nearly two thirds (65%) of participating healthcare 238 workers still exhibited some form of olfactory dysfunction with more than a third (37%) showing a clinically 239 reduced sense of smell. In comparison, approximately a quarter (24%) of individuals without prior SARS-240 CoV-2 infection displayed clinically altered sense of smell. Further, amongst the individuals who 241 experienced SARS-CoV-2 infection, about half (51%) experienced parosmia, compared to only 5% in the 242 SARS-CoV-2 naive group; an increase of parosmia due to COVID-19 with 46 percentage points. More 243 specifically, the first wave of COVID-19 nearly doubled the prevalence of olfactory dysfunction in this 244 population from 20% to 36% and increased the prevalence of any form of olfactory dysfunction by a full 41 245 percentage points compared to individuals whose immune system was never exposed to the virus. Perhaps 246 even more striking, 24% of all tested COVID-19 survivors still experience parosmia 2.6 years after COVID-247 19 diagnosis, nearly half of which experience medium to severe symptoms.

Olfactory dysfunction is common also in the general population. Before the COVID-19 pandemic,
the rate of quantitative olfactory dysfunction was consistently estimated to approximately 20% [16,19]. In

250 our control sample of COVID-19 naïve individuals, we found a similar percentage with 20% of the 251 participants exhibiting quantitative olfactory dysfunction. As outlined above, olfactory dysfunction can have 252 different etiologies, including sinonasal disease, traumatic brain injury, neurodegenerative diseases, and 253 more [20,30]. It is therefore crucial to assess the prevalence of olfactory dysfunction due to COVID-19 254 against this background of olfactory dysfunction in the population. Our data suggests that COVID-19 255 roughly doubles the prevalence of quantitative olfactory dysfunction in the general population. A different 256 and bleaker picture emerges when considering also qualitative olfactory dysfunction, i.e., parosmia and 257 phantosmia. These conditions are relatively rare in the general population, which is also reflected by the 258 prevalence of 5% in the COVID-19 naïve group aligning with prior assessments of Swedish samples 259 [31,32]. However, nearly half of the COVID+ group exhibited qualitative olfactory dysfunction on average 260 15 months after contracting the disease.

Our study shows that 37% of COVID+ individuals still experienced reduction in their olfactory performance, even on average 15 months after COVID-19 onset. This percentage is higher compared to similar studies, see among others [13]. Notably, while there was a significant difference in overall olfactory functions between the two groups, as operationalized by the TDI scores, this difference was restricted to performance on the odor quality discrimination and odor identification subtests, but not in odor detection threshold This finding suggests that a potential underlying driver of the differences is the large difference in parosmia that might distort the odor quality of the odors included in the two-odor subtest.

It is not yet completely understood how a SARS-CoV-2 infection leads to olfactory dysfunction. The leading explanation of the acute olfactory dysfunction seen in patients is linked to the ability of the virus to infect human cells that co-express ACE2 and TMPRSS2 proteins, such as the sustentacular cells of the olfactory mucosa [33]. Upon infection, these cells degenerate, which disturbs the local environment and crucially results in cell death of olfactory receptor neurons and consequently olfactory dysfunction [33,34]. The olfactory system demonstrates however a very good ability to regenerate [35], which might explain

why most SARS-CoV-2 infected individuals regain olfactory abilities within weeks following the acutephase [5,9]. It is not yet clear why some individuals do not completely regain their olfactory abilities.

276 Recent data from the verbal track-and-trace program in the United Kingdom suggests that fewer 277 individuals report subjective olfactory dysfunction after infection with the later Omicron (BA.1. and BA.2) 278 variants than the original virus variants [36]. We do not know what specific virus variants individuals in our 279 sample was infected with or exactly what proportions of virus variants dominated in our specific sample, 280 but random sampling of the Stockholm population at the time indicated that the Wildtype and, to a lesser 281 extent the B.1.1/B.1.1.29 and B.1.1.1/C.14 strains, dominated [29]. Although tentative data suggest that 282 fewer individuals report subjective olfactory dysfunction after Omicron variant infection, these are based 283 on subjective data collected only a day or two after testing positive. Whether potential lower numbers of 284 olfactory dysfunction after Omicron or other later variants could be due to a delay in onset of olfactory 285 dysfunction that in turn might affect long-term outcomes, remains to be determined. Future studies should 286 address differences between virus variants in effects on olfactory function.

287 A significant strength of the present study is that all participants were continuously serologically 288 monitored from the onset of the pandemic, meaning that it can be firmly established not only that all 289 participants in the COVID+ group had undergone a SARS-CoV-2 infection, but also when. Critically, we 290 can firmly claim that no participants in the COVID- group, a control group from the same cohort, had 291 seroconverted at any point before sensory testing, thereby giving us a true baseline for existing olfactory 292 dysfunction prevalence. Likewise, most studies assessing olfactory dysfunction in a general population 293 suffer from collider bias, i.e., that individuals that experience olfactory problems are more likely to volunteer 294 for the study in the first place, thereby erroneously increasing the prevalence of dysfunction. By using a 295 control group undergoing the same recruitment strategy as the target group and the population being 296 healthcare professionals, possibly better informed and willing to participate in research without personal 297 gain, it can be assumed that collider bias acts in equal strength across groups. It can be argued that healthcare 298 workers, in general, are a group consisting of generally more healthy individuals than the general population.

299 Olfactory problems and their underlying mechanisms therefore could be different than other populations. 300 However, the fact that we obtained identical prevalence of olfactory dysfunction in the COVID- group as 301 the only two previously published prevalence studies in a Swedish sample do not support this notion [31,32]. 302 That said, the strengths mentioned come from the fact that we sampled from a smaller group of closely 303 monitored individuals with a profession that was unfortunately highly taxed for time during a pandemic. 304 This meant that obtaining data from a large and diverse sample was not possible. In addition to the relatively 305 small sample sizes, the COVID+ group had nearly double the participants compared to the COVID- groups, 306 which we aim to statistically control for by using methods such as the Wilcoxon rank sum test. These tests 307 do not assume equal sample sizes and are therefore robust against differences in sample size. Another 308 weakness is that the sex ratio in both groups were skewed with more women participating, which, however, 309 also reflects the underlying population of healthcare workers. Women are also known to be slightly more 310 prone to experiencing long-term effects on olfactory function after upper respiratory infections [37]. 311 Whether the skewed sex ratio of our sample affects the generalization of our results to other populations of 312 healthcare workers is not known.

## 313 Conclusion

We show that COVID-19 nearly doubles the already large prevalence of quantitative olfactory dysfunction to approximately 37% in a sample of healthcare workers. Furthermore, about half of the COVID-19 survivors exhibit qualitative olfactory dysfunction. Finally, nearly two thirds (65%) of COVID-19 survivors in this group of healthcare workers exhibit olfactory dysfunction of some form 15 months and 24% reported parosmia 2.6 years after infection. Given the length of time, it is possible that these olfactory problems may not be fully reversible in a plurality of individuals.

## 321 Authorship contribution

ALW, NG, ET, SH, CT, JKO, & JNL contributed to design and acquisition, JF, AT, & JNL analysed and
wrote the manuscript, all authors contributed to the interpretation of the data, revisions of the manuscript,
and provided final approval of the article before submission.

325

# 326 **Conflict of interest**

327 No conflicts of interest are reported for all authors.

328

# 329 Funding

330 Funding was provided by grants awarded to JNL and CT from the Knut and Alice Wallenberg Foundation

331 (KAW 2018.0152 and KAW 2020.0182, respectively), the Swedish Research Council (2021-06527) and a

donation from Stiftelsen Bygg-Göta för Vetenskaplig forskning to JNL, as well as the Swedish Heart Lung

**333** Foundation to CT (20210017 HLF). JF is supported by the Fonds de Recherche du Ouébec – Santé, the

334 Natural Sciences and Engineering Council of Canada (RGPIN-2022-04813) and the Canadian Institutes of

Health Research (PJT 173514). The funders had no role in study design, data collection and analysis,

decision to publish, or preparation of the manuscript.

337

# 338 **References**

- Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakke AJ, et al. Recent Smell Loss Is the
   Best Predictor of COVID-19 Among Individuals With Recent Respiratory Symptoms. Chem
   Senses. 2021;46. doi:10.1093/chemse/bjaa081
- 2. Rudberg A-S, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-CoV-2
- exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. 2020;11:
  5064. doi:10.1038/s41467-020-18848-0


- 345 3. Bianco MR, Modica DM, Drago GD, Azzolina A, Mattina G, De Natale M, et al. Alteration of Smell
- and Taste in Asymptomatic and Symptomatic COVID-19 Patients in Sicily, Italy. Ear Nose Throat
  J. 2021;100: 182S-185S. doi:10.1177/0145561320981447
- 4. Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More Than Smell-COVID-19
  Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. Chem Senses. 2020;45:
  609–622. doi:10.1093/chemse/bjaa041
- 5. Bussiere N, Mei J, Levesque-Boissonneault C, Blais M, Carazo S, Gros-Louis F, et al. Persisting
  chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month followup. Chem Senses. 2022;47. doi:10.1093/chemse/bjac010
- 6. McWilliams MP, Coelho DH, Reiter ER, Costanzo RM. Recovery from Covid-19 smell loss: Twoyears of follow up. Am J Otolaryngol. 2022;43: 103607. doi:10.1016/j.amjoto.2022.103607
- 7. Boscolo-Rizzo P, Tofanelli M, Zanelli E, Gardenal N, Tirelli G. COVID-19-Related Quantitative and
   Qualitative Olfactory and Gustatory Dysfunction: Long-Term Prevalence and Recovery Rate. ORL
   J Otorhinolaryngol Relat Spec. 2022; 1–5. doi:10.1159/000525861
- 8. Capelli M, Gatti P. Anosmia in the first coronavirus disease 2019 outbreak in Europe: functional
  recovery after eight months. J Laryngol Otol. 2021;135: 224–228.
- doi:10.1017/S0022215121000670
- 362 9. Bussière N, Mei J, Lévesque-Boissonneault C, Blais M, Carazo S, Gros-Louis F, et al. Chemosensory
   363 Dysfunctions Induced by COVID-19 Can Persist up to 7 Months: A Study of Over 700 Healthcare
   364 Workers. Chem Senses. 2021;46. doi:10.1093/chemse/bjab038
- 10. Hopkins C, Surda P, Vaira LA, Lechien JR, Safarian M, Saussez S, et al. Six month follow-up of selfreported loss of smell during the COVID-19 pandemic. Rhinology. 2021;59: 26–31.
  doi:10.4193/Rhin20.544
- 11. Lechien JR, Chiesa-Estomba CM, Beckers E, Mustin V, Ducarme M, Journe F, et al. Prevalence and
  6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. J
  Intern Med. 2021;290: 451–461. doi:10.1111/joim.13209
- 12. Ohla K, Veldhuizen MG, Green T, Hannum ME, Bakke AJ, Moein ST, et al. A follow-up on
  quantitative and qualitative olfactory dysfunction and other symptoms in patients recovering from
  COVID-19 smell loss. Rhinology. 2022;60: 207–217. doi:10.4193/Rhin21.415
- Bianco MR, Ralli M, Minni A, Greco A, de Vincentiis M, Allegra E. Evaluation of olfactory
  dysfunction persistence after COVID-19: a prospective study. Eur Rev Med Pharmacol Sci.
  2022;26: 1042–1048. doi:10.26355/eurrev\_202202\_28014
- 14. Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. Ratings of overall olfactory function.
  Chem Senses. 2003;28: 691–694. doi:10.1093/chemse/bjg061
- 379 15. Lötsch J, Hummel T. Clinical Usefulness of Self-Rated Olfactory Performance-A Data Science380 Based Assessment of 6000 Patients. Chem Senses. 2019;44: 357–364. doi:10.1093/chemse/bjz029

381 16. Brämerson A, Johansson L, Ek L, Nordin S, Bende M. Prevalence of olfactory dysfunction: the
382 skövde population-based study. Laryngoscope. 2004;114: 733–737. doi:10.1097/00005537383 200404000-00026

- 384 17. Devanand DP, Lee S, Manly J, Andrews H, Schupf N, Masurkar A, et al. Olfactory identification
  385 deficits and increased mortality in the community. Ann Neurol. 2015;78: 401–411.
  386 doi:10.1002/ana.24447
- 18. Karpa MJ, Gopinath B, Rochtchina E, Jie Jin Wang, Cumming RG, Sue CM, et al. Prevalence and neurodegenerative or other associations with olfactory impairment in an older community. J Aging
  Health. 2010;22: 154–168. doi:10.1177/0898264309353066
- 19. Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction.
  Laryngoscope. 2004;114: 1764–1769. doi:10.1097/00005537-200410000-00017
- 392 20. Temmel AFP, Quint C, Schickinger-Fischer B, Klimek L, Stoller E, Hummel T. Characteristics of
  393 olfactory disorders in relation to major causes of olfactory loss. Arch Otolaryngol Head Neck Surg.
  394 2002;128: 635–641. doi:10.1001/archotol.128.6.635
- 21. Landis BN, Frasnelli J, Croy I, Hummel T. Evaluating the clinical usefulness of structured
  questions in parosmia assessment. Laryngoscope. 2010;120: 1707–1713. doi:10.1002/lary.20955
- 397 22. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification
  398 Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94: 176–178.
  399 doi:10.1288/00005537-198402000-00004
- 400 23. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. "Sniffin" sticks': olfactory performance
  401 assessed by the combined testing of odor identification, odor discrimination and olfactory threshold.
  402 Chem Senses. 1997;22: 39–52. doi:10.1093/chemse/22.1.39
- 403 24. Wahlster S, Hartog C. Coronavirus disease 2019 aftermath: psychological trauma in ICU
  404 healthcare workers. Curr Opin Crit Care. 2022;28: 686–694. doi:10.1097/MCC.00000000000994
- Lee BEC, Ling M, Boyd L, Olsson C, Sheen J. The prevalence of probable mental health disorders
  among hospital healthcare workers during COVID-19: A systematic review and meta-analysis. J
  Affect Disord. 2023;330: 329–345. doi:10.1016/j.jad.2023.03.012
- Tan BKJ, Han R, Zhao JJ, Tan NKW, Quah ESH, Tan CJ-W, et al. Prognosis and persistence of
  smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling
  of recovery curves. BMJ. 2022;378: e069503. doi:10.1136/bmj-2021-069503
- 411 27. Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin' Sticks normative data
  412 based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol. 2019;276: 719–728.
  413 doi:10.1007/s00405-018-5248-1
- 414 28. Hober S, Hellström C, Olofsson J, Andersson E, Bergström S, Jernbom Falk A, et al. Systematic
  415 evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological
  416 COVID-19 assay. Clin Transl Immunology. 2021;10: e1312. doi:10.1002/cti2.1312
- 417 29. Dyrdak R, Albert J. Utredning av den initiala smittspridningen avSARS-CoV-2 till och inom Sverige.
- 418 Swedish Government; 2021 Oct. Report No.: 2021:89.

- 30. Hummel T, Landis BN, Rombaux P. Disrupted Odor Perception. In: Buettner A, editor. Springer
  handbook of odor. Cham: Springer International Publishing; 2017. pp. 79–80. doi:10.1007/978-3319-26932-0\_31
- 422 31. Nordin S, Brämerson A, Millqvist E, Bende M. Prevalence of parosmia: the Skövde population-based
  423 studies. Rhinology. 2007;45: 50–53.
- 424 32. Olofsson JK, Ekesten F, Nordin S. Olfactory distortions in the general population. Sci Rep. 2022;12:
  425 9776. doi:10.1038/s41598-022-13201-5
- 33. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al. COVID-19 and
  the Chemical Senses: Supporting Players Take Center Stage. Neuron. 2020;107: 219–233.
  doi:10.1016/j.neuron.2020.06.032
- 429 34. Xydakis MS, Albers MW, Holbrook EH, Lyon DM, Shih RY, Frasnelli JA, et al. Post-viral effects of
  430 COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021;20: 753–761.
  431 doi:10.1016/S1474-4422(21)00182-4
- 432 35. Reden J, Mueller A, Mueller C, Konstantinidis I, Frasnelli J, Landis BN, et al. Recovery of olfactory
  433 function following closed head injury or infections of the upper respiratory tract. Arch Otolaryngol
  434 Head Neck Surg. 2006;132: 265–269. doi:10.1001/archotol.132.3.265
- 435 36. Vihta K-D, Pouwels KB, Peto TE, Pritchard E, House T, Studley R, et al. Omicron-associated changes
  436 in sars-cov-2 symptoms in the united kingdom. medRxiv. 2022. doi:10.1101/2022.01.18.22269082
- 437 37. Seiden AM. Postviral olfactory loss. Otolaryngol Clin North Am. 2004;37: 1159–1166.
- 438 doi:10.1016/j.otc.2004.06.007
- 439

# 441 Supporting Information



Supplementary Figure S1. Scatterplot illustrating the association between TDI score and (A) days since infection or (B) age of individuals who had had COVID-19 (COVID+, in orange) and COVID-19 naïve individuals (COVID-, in blue). Spearman correlations showed that TDI score was not significantly affected by the number of days since infection (N = 71, r = -.1, p = .43), but significantly declined with age in the COVID+ group (r = -.28, p = .005) but not in the COVID- group (r = -.27, p =.09).